CN110100001A - 评估磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 - Google Patents
评估磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 Download PDFInfo
- Publication number
- CN110100001A CN110100001A CN201680090179.1A CN201680090179A CN110100001A CN 110100001 A CN110100001 A CN 110100001A CN 201680090179 A CN201680090179 A CN 201680090179A CN 110100001 A CN110100001 A CN 110100001A
- Authority
- CN
- China
- Prior art keywords
- drug
- hla
- anaphylaxis
- allele
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 61
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 206010002198 Anaphylactic reaction Diseases 0.000 title claims abstract description 48
- 230000036783 anaphylactic response Effects 0.000 title claims abstract description 48
- 208000003455 anaphylaxis Diseases 0.000 title claims abstract description 48
- 229960005404 sulfamethoxazole Drugs 0.000 title claims abstract description 23
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 21
- UQVADGKRJSPTBY-UHFFFAOYSA-N 4-benzyl-5-methoxypyrimidin-2-amine Chemical compound O(C)C=1C(=NC(=NC1)N)CC1=CC=CC=C1 UQVADGKRJSPTBY-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 208000019872 Drug Eruptions Diseases 0.000 claims abstract description 27
- 208000032678 Fixed drug eruption Diseases 0.000 claims abstract description 16
- 230000003115 biocidal effect Effects 0.000 claims abstract description 16
- 208000012587 fixed pigmented erythema Diseases 0.000 claims abstract description 16
- 206010059284 Epidermal necrosis Diseases 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 208000024891 symptom Diseases 0.000 claims abstract description 11
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 11
- 231100000331 toxic Toxicity 0.000 claims abstract description 11
- 230000002588 toxic effect Effects 0.000 claims abstract description 11
- 230000000977 initiatory effect Effects 0.000 claims abstract description 8
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 33
- 102000006390 HLA-B Antigens Human genes 0.000 claims description 33
- 108700028369 Alleles Proteins 0.000 claims description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000003870 depth resolved spectroscopy Methods 0.000 claims description 3
- 208000009743 drug hypersensitivity syndrome Diseases 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 claims description 2
- 208000022143 drug rash with eosinophilia and systemic symptoms Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000030961 allergic reaction Diseases 0.000 claims 4
- 230000002052 anaphylactic effect Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 description 9
- 206010013700 Drug hypersensitivity Diseases 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 201000005311 drug allergy Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
提供一种评估抗生素磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法，其中药物过敏反应包括：斑丘疹、固定型药疹、史帝文生－琼森症候群、毒性表皮坏死症、药物疹合并嗜伊红血症及全身症状。特定的HLA基因型与抗生素磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应有关。
Description
PCT国内申请，说明书已公开。
Claims (14)
- PCT国内申请，权利要求书已公开。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410227498.9A CN118109579A (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/103537 WO2018076228A1 (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410227498.9A Division CN118109579A (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110100001A true CN110100001A (zh) | 2019-08-06 |
| CN110100001B CN110100001B (zh) | 2024-03-01 |
Family
ID=62024275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410227498.9A Pending CN118109579A (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
| CN201680090179.1A Active CN110100001B (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410227498.9A Pending CN118109579A (zh) | 2016-10-27 | 2016-10-27 | 评估磺胺甲基异噁唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11028437B2 (zh) |
| EP (1) | EP3533871A4 (zh) |
| JP (1) | JP6790260B2 (zh) |
| KR (1) | KR102305340B1 (zh) |
| CN (2) | CN118109579A (zh) |
| AU (1) | AU2016427922B9 (zh) |
| CA (1) | CA3041556A1 (zh) |
| WO (1) | WO2018076228A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116209758A (zh) * | 2020-08-18 | 2023-06-02 | 长庚医疗财团法人林口长庚纪念医院 | 检测磺胺衍生物的抗癫痫药物引起的药物过敏反应的方法及试剂盒，以及试剂盒的用途 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120238455A1 (en) * | 2011-03-14 | 2012-09-20 | Riken | Method for diagnosing drug eruption risk induced by antiepileptic drug based on single nucleotide polymorphism in 21.33 region of short arm of chromosome 6 |
| CN104450912A (zh) * | 2014-12-10 | 2015-03-25 | 苏州旷远生物分子技术有限公司 | 用于检测人hla-b*1301基因的引物、探针、荧光pcr试剂盒和方法 |
| US20150218634A1 (en) * | 2012-10-23 | 2015-08-06 | Shandong Provincial Institute Of Dermatology And Venereology | Use of hla-b*1301 allele |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074667C (zh) * | 1997-08-21 | 2001-11-14 | 皮志华 | 一种治疗创伤药 |
| CN1362880A (zh) * | 1999-04-02 | 2002-08-07 | 布赖汉姆妇女医院 | 免疫调制聚合物 |
| CN102918396B (zh) | 2010-04-12 | 2016-05-11 | 中央研究院 | 利用人类白血球抗原(hla)筛检预测药物不良反应的方法 |
| EP2723888B1 (en) | 2011-06-23 | 2017-01-11 | Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN103173538B (zh) | 2013-01-11 | 2015-02-18 | 中国医学科学院皮肤病研究所 | 用于检测hla-b*1301基因的试剂盒 |
-
2016
- 2016-10-27 AU AU2016427922A patent/AU2016427922B9/en active Active
- 2016-10-27 WO PCT/CN2016/103537 patent/WO2018076228A1/zh unknown
- 2016-10-27 CN CN202410227498.9A patent/CN118109579A/zh active Pending
- 2016-10-27 JP JP2019522658A patent/JP6790260B2/ja active Active
- 2016-10-27 KR KR1020197015031A patent/KR102305340B1/ko active IP Right Grant
- 2016-10-27 EP EP16919924.7A patent/EP3533871A4/en active Pending
- 2016-10-27 CA CA3041556A patent/CA3041556A1/en active Pending
- 2016-10-27 CN CN201680090179.1A patent/CN110100001B/zh active Active
-
2019
- 2019-04-03 US US16/374,651 patent/US11028437B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120238455A1 (en) * | 2011-03-14 | 2012-09-20 | Riken | Method for diagnosing drug eruption risk induced by antiepileptic drug based on single nucleotide polymorphism in 21.33 region of short arm of chromosome 6 |
| US20150218634A1 (en) * | 2012-10-23 | 2015-08-06 | Shandong Provincial Institute Of Dermatology And Venereology | Use of hla-b*1301 allele |
| CN104450912A (zh) * | 2014-12-10 | 2015-03-25 | 苏州旷远生物分子技术有限公司 | 用于检测人hla-b*1301基因的引物、探针、荧光pcr试剂盒和方法 |
Non-Patent Citations (3)
| Title |
|---|
| CHUN-YU WEI等: "A recent update of pharmacogenomics in drug-induced severe skin reactions", 《DRUG METABOLISM AND PHARMACOKINETICS》 * |
| LONJOU, CHRISTINE等: "A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs", 《PHARMACOGENETICS AND GENOMICS》 * |
| MARK JEAN-AANKOHMD等: "Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children", 《JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110100001B (zh) | 2024-03-01 |
| US11028437B2 (en) | 2021-06-08 |
| CA3041556A1 (en) | 2018-05-03 |
| JP2019533457A (ja) | 2019-11-21 |
| EP3533871A1 (en) | 2019-09-04 |
| AU2016427922A1 (en) | 2019-05-16 |
| KR20190084061A (ko) | 2019-07-15 |
| KR102305340B1 (ko) | 2021-09-28 |
| JP6790260B2 (ja) | 2020-11-25 |
| EP3533871A4 (en) | 2020-05-06 |
| WO2018076228A1 (zh) | 2018-05-03 |
| US20190226023A1 (en) | 2019-07-25 |
| AU2016427922B2 (en) | 2021-04-01 |
| AU2016427922B9 (en) | 2021-08-19 |
| CN118109579A (zh) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hicks et al. | Saliva microRNA differentiates children with autism from peers with typical and atypical development | |
| Gunawardhana et al. | Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma | |
| Akala et al. | Antimalarial drug sensitivity profile of western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay and molecular analysis | |
| Nath et al. | Linkage at 12q24 with systemic lupus erythematosus (SLE) is established and confirmed in Hispanic and European American families | |
| US20230151358A1 (en) | Single step sample preparation for next generation sequencing | |
| CN104450707B (zh) | 一种血清miRNA生物标志物的应用 | |
| Qian et al. | Expression of nuclear factor, erythroid 2-like 2-mediated genes differentiates tuberculosis | |
| CN110100001A (zh) | 评估磺胺甲基异恶唑及/或甲氧苄氨嘧啶引发药物过敏反应风险的方法 | |
| Carvalho et al. | Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients | |
| Tang et al. | Assay for transposase-accessible chromatin using sequencing analysis reveals a widespread increase in chromatin accessibility in psoriasis | |
| Van Rensburg et al. | Transcriptomics: the key to biomarker discovery during tuberculosis? | |
| Sadowy et al. | Relationships among streptococci from the mitis group, misidentified as Streptococcus pneumoniae | |
| Kaforou et al. | Host RNA signatures for diagnostics: an example from paediatric tuberculosis in Africa | |
| CN110904208B (zh) | 与cv-a6型手足口病重症易感性相关的snp位点及其应用 | |
| CN105506164A (zh) | 一种检测青春型精神分裂症易感性的试剂盒 | |
| Braunstein et al. | The IFN-regulated gene signature is elevated in SCLE and DLE and correlates with CLASI score | |
| CN108342457A (zh) | Hla-b5801等位基因的检测试剂盒及其应用 | |
| Tay et al. | Distinct transcriptomic and metabolomic profiles characterize NSAID-induced urticaria/angioedema patients undergoing aspirin desensitization | |
| CN107022613B (zh) | 一种与非综合征型唇腭裂诊断相关的snp标志物及其应用 | |
| Wen et al. | Gene Expression and Splicing QTL Analysis of Blood Cells in African American Participants from the Jackson Heart Study | |
| KR102481211B1 (ko) | 만성 감각신경성 이명 진단용 snp 마커 및 이를 이용한 진단 방법 | |
| CN103820555A (zh) | 一种利用连锁不平衡在家系中筛查Wilson disease基因突变的方法 | |
| CN109609616B (zh) | Hla-a*02:01和hla-c*01:02在丹参酮所致药疹中的用途 | |
| Yushina et al. | Studying the impact of the genetic polymorphisms of chemokines on the arterial pressure level and kidney function in patient with the chronic glomerulonephritis | |
| EP3565635B1 (en) | Methods for diagnosing asthma and compositions for use in targeting the th2 pathway in the treatment of asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |